Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report
Descripción del Articulo
Irreversible cardiotoxicity (IC) induced by trastuzumab (TZB) is a rare but serious adverse event. As a result, its characteristics and the specific factors related to exposure remain poorly understood. This study aims to synthesize and evaluate the existing evidence on IC. We presented a pharmacovi...
Autores: | , , , |
---|---|
Formato: | artículo |
Fecha de Publicación: | 2025 |
Institución: | Instituto Nacional Cardiovascular |
Repositorio: | Archivos peruanos de cardiología y cirugía cardiovascular |
Lenguaje: | inglés |
OAI Identifier: | oai:apcyccv.org.pe:article/456 |
Enlace del recurso: | https://apcyccv.org.pe/index.php/apccc/article/view/456 |
Nivel de acceso: | acceso abierto |
Materia: | Breast Neoplasms Cardiotoxicity Trastuzumab Pharmacovigilance |
id |
REVINCOR_35e3f685ea147ac6198ebcb96425b1f3 |
---|---|
oai_identifier_str |
oai:apcyccv.org.pe:article/456 |
network_acronym_str |
REVINCOR |
network_name_str |
Archivos peruanos de cardiología y cirugía cardiovascular |
repository_id_str |
|
dc.title.none.fl_str_mv |
Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report |
title |
Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report |
spellingShingle |
Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report Lechuga-Noa, Víctor E. Breast Neoplasms Cardiotoxicity Trastuzumab Pharmacovigilance Breast Neoplasms Cardiotoxicity Trastuzumab Pharmacovigilance |
title_short |
Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report |
title_full |
Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report |
title_fullStr |
Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report |
title_full_unstemmed |
Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report |
title_sort |
Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case report |
dc.creator.none.fl_str_mv |
Lechuga-Noa, Víctor E. Rodríguez-Tanta, L. Yesenia Solis-Yucra, Tania del Pilar Rojo Rosales, Efraín Cesar Lechuga-Noa, Víctor E. Rodríguez-Tanta, L. Yesenia Solis-Yucra, Tania del Pilar Rojo Rosales, Efraín Cesar |
author |
Lechuga-Noa, Víctor E. |
author_facet |
Lechuga-Noa, Víctor E. Rodríguez-Tanta, L. Yesenia Solis-Yucra, Tania del Pilar Rojo Rosales, Efraín Cesar |
author_role |
author |
author2 |
Rodríguez-Tanta, L. Yesenia Solis-Yucra, Tania del Pilar Rojo Rosales, Efraín Cesar |
author2_role |
author author author |
dc.subject.none.fl_str_mv |
Breast Neoplasms Cardiotoxicity Trastuzumab Pharmacovigilance Breast Neoplasms Cardiotoxicity Trastuzumab Pharmacovigilance |
topic |
Breast Neoplasms Cardiotoxicity Trastuzumab Pharmacovigilance Breast Neoplasms Cardiotoxicity Trastuzumab Pharmacovigilance |
description |
Irreversible cardiotoxicity (IC) induced by trastuzumab (TZB) is a rare but serious adverse event. As a result, its characteristics and the specific factors related to exposure remain poorly understood. This study aims to synthesize and evaluate the existing evidence on IC. We presented a pharmacovigilance case of longterm IC and conducted a systematic review (SR) of the clinical manifestations of cases reported worldwide. We reported the case using the CARE guidelines checklist and assessed the causality using the modified Algorithm of Karch and Lasagna. Following PRISMA guidelines, we conducted the SR using defined terms in PubMed, Embase, Scopus, and Web of Science from inception until June 2023. This SR included five case reports, including the pharmacovigilance case reported by us. While patients exhibited different severe clinical characteristics, receiving TZB at a 6 mg/kg dose was consistent. Despite varying treatment durations, the median time of IC diagnosis was 10 months, and the average difference between the basal and the final left ventricular ejection fraction was roughly 30%. According to the modified Karch and Lasagna algorithm, all cases were ranged from possible to probable. While TZB is generally considered a reversible cardiotoxic antineoplastic, clinicians and regulators must be aware of the potential IC risk with long-term manifestations. Vigilant cardiac monitoring and further research are crucial to better understanding and managing this serious adverse event. |
publishDate |
2025 |
dc.date.none.fl_str_mv |
2025-03-21 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Peer-Review article Artículo evaluado por pares |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
https://apcyccv.org.pe/index.php/apccc/article/view/456 10.47487/apcyccv.v6i1.456 |
url |
https://apcyccv.org.pe/index.php/apccc/article/view/456 |
identifier_str_mv |
10.47487/apcyccv.v6i1.456 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://apcyccv.org.pe/index.php/apccc/article/view/456/615 https://apcyccv.org.pe/index.php/apccc/article/view/456/616 |
dc.rights.none.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Instituto Nacional Cardiovascular “Carlos Alberto Peschiera Carrillo” – INCOR, EsSalud |
publisher.none.fl_str_mv |
Instituto Nacional Cardiovascular “Carlos Alberto Peschiera Carrillo” – INCOR, EsSalud |
dc.source.none.fl_str_mv |
Archivos Peruanos de Cardiología y Cirugía Cardiovascular; Vol. 6 No. 1 (2025); 1-10 Archivos Peruanos de Cardiología y Cirugía Cardiovascular; Vol. 6 Núm. 1 (2025); 1-10 2708-7212 10.47487/apcyccv.v6i1 reponame:Archivos peruanos de cardiología y cirugía cardiovascular instname:Instituto Nacional Cardiovascular instacron:INCOR |
instname_str |
Instituto Nacional Cardiovascular |
instacron_str |
INCOR |
institution |
INCOR |
reponame_str |
Archivos peruanos de cardiología y cirugía cardiovascular |
collection |
Archivos peruanos de cardiología y cirugía cardiovascular |
repository.name.fl_str_mv |
|
repository.mail.fl_str_mv |
|
_version_ |
1844898426971488256 |
spelling |
Irreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case reportIrreversible cardiotoxicity induced by trastuzumab: a systematic review based on a pharmacovigilance case reportLechuga-Noa, Víctor E.Rodríguez-Tanta, L. YeseniaSolis-Yucra, Tania del PilarRojo Rosales, Efraín CesarLechuga-Noa, Víctor E.Rodríguez-Tanta, L. YeseniaSolis-Yucra, Tania del PilarRojo Rosales, Efraín CesarBreast NeoplasmsCardiotoxicityTrastuzumabPharmacovigilanceBreast NeoplasmsCardiotoxicityTrastuzumabPharmacovigilanceIrreversible cardiotoxicity (IC) induced by trastuzumab (TZB) is a rare but serious adverse event. As a result, its characteristics and the specific factors related to exposure remain poorly understood. This study aims to synthesize and evaluate the existing evidence on IC. We presented a pharmacovigilance case of longterm IC and conducted a systematic review (SR) of the clinical manifestations of cases reported worldwide. We reported the case using the CARE guidelines checklist and assessed the causality using the modified Algorithm of Karch and Lasagna. Following PRISMA guidelines, we conducted the SR using defined terms in PubMed, Embase, Scopus, and Web of Science from inception until June 2023. This SR included five case reports, including the pharmacovigilance case reported by us. While patients exhibited different severe clinical characteristics, receiving TZB at a 6 mg/kg dose was consistent. Despite varying treatment durations, the median time of IC diagnosis was 10 months, and the average difference between the basal and the final left ventricular ejection fraction was roughly 30%. According to the modified Karch and Lasagna algorithm, all cases were ranged from possible to probable. While TZB is generally considered a reversible cardiotoxic antineoplastic, clinicians and regulators must be aware of the potential IC risk with long-term manifestations. Vigilant cardiac monitoring and further research are crucial to better understanding and managing this serious adverse event.Irreversible cardiotoxicity (IC) induced by trastuzumab (TZB) is a rare but serious adverse event. As a result, its characteristics and the specific factors related to exposure remain poorly understood. This study aims to synthesize and evaluate the existing evidence on IC. We presented a pharmacovigilance case of longterm IC and conducted a systematic review (SR) of the clinical manifestations of cases reported worldwide. We reported the case using the CARE guidelines checklist and assessed the causality using the modified Algorithm of Karch and Lasagna. Following PRISMA guidelines, we conducted the SR using defined terms in PubMed, Embase, Scopus, and Web of Science from inception until June 2023. This SR included five case reports, including the pharmacovigilance case reported by us. While patients exhibited different severe clinical characteristics, receiving TZB at a 6 mg/kg dose was consistent. Despite varying treatment durations, the median time of IC diagnosis was 10 months, and the average difference between the basal and the final left ventricular ejection fraction was roughly 30%. According to the modified Karch and Lasagna algorithm, all cases were ranged from possible to probable. While TZB is generally considered a reversible cardiotoxic antineoplastic, clinicians and regulators must be aware of the potential IC risk with long-term manifestations. Vigilant cardiac monitoring and further research are crucial to better understanding and managing this serious adverse event.Instituto Nacional Cardiovascular “Carlos Alberto Peschiera Carrillo” – INCOR, EsSalud2025-03-21info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer-Review articleArtículo evaluado por paresapplication/pdfapplication/pdfhttps://apcyccv.org.pe/index.php/apccc/article/view/45610.47487/apcyccv.v6i1.456Archivos Peruanos de Cardiología y Cirugía Cardiovascular; Vol. 6 No. 1 (2025); 1-10Archivos Peruanos de Cardiología y Cirugía Cardiovascular; Vol. 6 Núm. 1 (2025); 1-102708-721210.47487/apcyccv.v6i1reponame:Archivos peruanos de cardiología y cirugía cardiovascularinstname:Instituto Nacional Cardiovascularinstacron:INCORenghttps://apcyccv.org.pe/index.php/apccc/article/view/456/615https://apcyccv.org.pe/index.php/apccc/article/view/456/616Derechos de autor 2025 La revista es titular de la primera publicación, luego el autor dando crédito a la primera publicación.https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessoai:apcyccv.org.pe:article/4562025-06-23T23:12:10Z |
score |
12.615219 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).